$CERS
CERUS CORP Stock $cers

$cers Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000119312513316994 Filed on August 02, 2013

Income Statement

Concept	2013 Q2	2012 Q2
Revenue	$10.15M	$9.224M
YoY Change	10.04%	36.59%
Cost Of Revenue	$5.747M	$5.574M
YoY Change	3.1%	36.82%
Gross Profit	$4.403M	$3.650M
YoY Change	20.63%	36.24%
Gross Profit Margin	43.38%	39.57%
Selling, General & Admin	$7.954M	$6.686M
YoY Change	18.97%	7.72%
% of Gross Profit	180.65%	183.18%
Research & Development	$3.506M	$1.712M
YoY Change	104.79%	-14.14%
% of Gross Profit	79.63%	46.9%
Depreciation & Amortization	$110.0K	$190.0K
YoY Change	-42.11%	-24.0%
% of Gross Profit	2.5%	5.21%
Operating Expenses	$11.51M	$8.449M
YoY Change	36.24%	2.39%
Operating Profit	-$7.108M	-$4.799M
YoY Change	48.11%	-13.89%
Interest Expense	$107.0K	$135.0K
YoY Change	-20.74%
% of Operating Profit
Other Income/Expense, Net	$438.0K	$2.933M
YoY Change	-85.07%	-462.55%
Pretax Income	-$6.670M	-$1.866M
YoY Change	257.45%	-70.76%
Income Tax	$54.00K	$41.00K
% Of Pretax Income
Net Earnings	-$6.724M	-$1.907M
YoY Change	252.6%	-70.24%
Net Earnings / Revenue	-66.25%	-20.67%
Basic Earnings Per Share	-$0.10	-$0.04
Diluted Earnings Per Share	-$0.10	-$0.10
COMMON SHARES
Basic Shares Outstanding	69.73M shares	54.42M shares
Diluted Shares Outstanding	71.93M shares	55.24M shares

Balance Sheet

Concept	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$58.20M	$26.70M
YoY Change	117.98%	50.0%
Cash & Equivalents	$58.20M	$26.67M
Short-Term Investments		$0.00
Other Short-Term Assets	$200.0K	$1.000M
YoY Change	-80.0%	11.11%
Inventory	$12.76M	$9.400M
Prepaid Expenses	$739.0K
Receivables	$5.868M	$3.700M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$77.77M	$40.80M
YoY Change	90.61%	23.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.641M	$1.900M
YoY Change	-13.63%	-9.52%
Goodwill	$1.316M
YoY Change
Intangibles	$1.445M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$72.00K	$400.0K
YoY Change	-82.0%	-50.0%
Total Long-Term Assets	$4.778M	$5.300M
YoY Change	-9.85%	-13.11%
TOTAL ASSETS
Total Short-Term Assets	$77.77M	$40.80M
Total Long-Term Assets	$4.778M	$5.300M
Total Assets	$82.55M	$46.10M
YoY Change	79.06%	17.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.035M	$3.500M
YoY Change	43.86%	-25.53%
Accrued Expenses	$8.748M	$6.600M
YoY Change	32.55%	24.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.200M	$3.700M
YoY Change	-40.54%	94.74%
Total Short-Term Liabilities	$26.38M	$22.70M
YoY Change	16.22%	2.71%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$3.700M
YoY Change	-100.0%	68.18%
Other Long-Term Liabilities	$1.145M	$1.200M
YoY Change	-4.58%	-25.0%
Total Long-Term Liabilities	$1.145M	$4.900M
YoY Change	-76.63%	28.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.38M	$22.70M
Total Long-Term Liabilities	$1.145M	$4.900M
Total Liabilities	$27.60M	$27.50M
YoY Change	0.37%	6.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$476.8M
YoY Change
Common Stock	$70.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$54.95M	$18.50M
YoY Change
Total Liabilities & Shareholders Equity	$82.55M	$46.10M
YoY Change	79.06%	17.9%

Cashflow Statement

Concept	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$6.724M	-$1.907M
YoY Change	252.6%	-70.24%
Depreciation, Depletion And Amortization	$110.0K	$190.0K
YoY Change	-42.11%	-24.0%
Cash From Operating Activities	-$5.690M	-$5.390M
YoY Change	5.57%	-9.87%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	-$60.00K
YoY Change	150.0%	200.0%
Acquisitions
YoY Change
Other Investing Activities	-$10.00K	$90.00K
YoY Change	-111.11%	125.0%
Cash From Investing Activities	-$160.0K	$30.00K
YoY Change	-633.33%	50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-5.110M	570.0K
YoY Change	-996.49%	-218.75%
NET CHANGE
Cash From Operating Activities	-5.690M	-5.390M
Cash From Investing Activities	-160.0K	30.00K
Cash From Financing Activities	-5.110M	570.0K
Net Change In Cash	-10.96M	-4.790M
YoY Change	128.81%	-25.62%
FREE CASH FLOW
Cash From Operating Activities	-$5.690M	-$5.390M
Capital Expenditures	-$150.0K	-$60.00K
Free Cash Flow	-$5.540M	-$5.330M
YoY Change	3.94%	-10.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69736000	shares
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26667000
CY2013Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12800000	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.40
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10540000	shares
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	26383000
CY2013Q2	us-gaap	Secured Debt SecuredDebt	2157000
CY2013Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1985000
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3458000
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	531703000
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5035000
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	10290000
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1145000
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	54945000
CY2013Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	10290000
CY2013Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	2157000
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-476828000
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	153000
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8748000
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0
CY2013Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2157000
CY2013Q2	us-gaap	Fair Value Liabilities Measured On Recurring Basis Obligations FairValueLiabilitiesMeasuredOnRecurringBasisObligations	10290000
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2217000
CY2013Q2	us-gaap	Liabilities Liabilities	27603000
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	52000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	572000
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	70000
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82548000
CY2013Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	75000
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	72000
CY2013Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	739000
CY2013Q2	us-gaap	Goodwill Goodwill	1316000
CY2013Q2	us-gaap	Cost Method Investments CostMethodInvestments	0
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	304000
CY2013Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1445000
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5868000
CY2013Q2	us-gaap	Inventory Net InventoryNet	12762000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	200000
CY2013Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	8846000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	200000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	100000
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1641000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	200000
CY2013Q2	us-gaap	Assets Assets	82548000
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58201000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1445000
CY2013Q2	us-gaap	Other Assets Current OtherAssetsCurrent	200000
CY2013Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3916000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	200000
CY2013Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	46500000
CY2013Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0
CY2013Q2	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	12762000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2017000
CY2013Q2	us-gaap	Assets Current AssetsCurrent	77770000
CY2013Q2	cers	Debt Instrument Carrying Current DebtInstrumentCarryingCurrent	2157000
CY2013Q2	cers	Finite Lived Intangible Assets Amortization Expense Year Six FiniteLivedIntangibleAssetsAmortizationExpenseYearSix	200000
CY2013Q2	cers	Cumulative Outstanding Trade Receivables Major Customers Percentage CumulativeOutstandingTradeReceivablesMajorCustomersPercentage	0.64	pure
CY2013Q2	cers	Debt Instrument Carrying Non Current DebtInstrumentCarryingNonCurrent	0
CY2013Q2	cers	Leasehold Improvement Reflected In Other Non Current Liabilities LeaseholdImprovementReflectedInOtherNonCurrentLiabilities	700000
CY2013Q2	cers	Debt Instrument Unamortized Current DebtInstrumentUnamortizedCurrent	0
CY2013Q2	cers	Accrued Inventory AccruedInventory	3305000
CY2013Q2	cers	Leasehold Improvement Reflected In Accrued Liabilities LeaseholdImprovementReflectedInAccruedLiabilities	100000
CY2013Q2	cers	Outstanding Liability Related To Leasehold Improvements Current And Non Current OutstandingLiabilityRelatedToLeaseholdImprovementsCurrentAndNonCurrent	800000
CY2013Q2	cers	Cumulative Outstanding Trade Receivables Number Of Major Customers CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers	4	Customer
CY2013Q2	cers	Options And Other Stock Based Awards OptionsAndOtherStockBasedAwards	10600000	shares
CY2013Q2	cers	Debt Instrument Unamortized Noncurrent DebtInstrumentUnamortizedNoncurrent	0
CY2013Q2	cers	Performance Based Stock Options Outstanding PerformanceBasedStockOptionsOutstanding	50000	shares
CY2013Q2	cers	Finite Lived Intangible Assets Amortization Expense Year Eight FiniteLivedIntangibleAssetsAmortizationExpenseYearEight	100000
CY2013Q2	cers	Finite Lived Intangible Assets Amortization Expense Year Seven FiniteLivedIntangibleAssetsAmortizationExpenseYearSeven	200000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25497000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.40
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8504000	shares
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	2896000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25613000
CY2012Q4	us-gaap	Secured Debt SecuredDebt	7724000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2692000
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2575000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	478903000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7186000
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	5903000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1241000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	19107000
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	5903000
CY2012Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	4828000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-459852000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	77000
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7619000
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	7773000
CY2012Q4	us-gaap	Fair Value Liabilities Measured On Recurring Basis Obligations FairValueLiabilitiesMeasuredOnRecurringBasisObligations	5903000
CY2012Q4	us-gaap	Liabilities Liabilities	29812000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	471000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	56000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48919000
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	62000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	59000
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	638000
CY2012Q4	us-gaap	Goodwill Goodwill	1316000
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	304000
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1546000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4444000
CY2012Q4	us-gaap	Inventory Net InventoryNet	10180000
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6629000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1698000
CY2012Q4	us-gaap	Assets Assets	48919000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26696000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1546000
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2038000
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3551000
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	10268000
CY2012Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	49000
CY2012Q4	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	10180000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2017000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	43996000
CY2012Q4	cers	Debt Instrument Carrying Current DebtInstrumentCarryingCurrent	4857000
CY2012Q4	cers	Cumulative Outstanding Trade Receivables Major Customers Percentage CumulativeOutstandingTradeReceivablesMajorCustomersPercentage	0.59	pure
CY2012Q4	cers	Debt Instrument Carrying Non Current DebtInstrumentCarryingNonCurrent	2916000
CY2012Q4	cers	Debt Instrument Unamortized Current DebtInstrumentUnamortizedCurrent	29000
CY2012Q4	cers	Accrued Inventory AccruedInventory	2352000
CY2012Q4	cers	Cumulative Outstanding Trade Receivables Number Of Major Customers CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers	3	Customer
CY2012Q4	cers	Debt Instrument Unamortized Noncurrent DebtInstrumentUnamortizedNoncurrent	20000
	dei	Trading Symbol TradingSymbol	CERS
	dei	Entity Registrant Name EntityRegistrantName	CERUS CORP
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001020214
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The restricted stock units vest in three annual installments from the date of grant and are generally issuable at the end of the three-year vesting term
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	131000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64756000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.60
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14041000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	89000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentration of Credit Risk</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Pursuant to the Company’s investment policy, substantially all of the Company’s cash, cash equivalents and short-term investments are maintained at a major financial institution of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company’s investments carry high credit quality ratings, which is in accordance with its investment policy. At June 30, 2013, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company’s cash equivalents.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">  </p> <p style="MARGIN-TOP: 0px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Concentrations of credit risk with respect to trade receivables exist. However, in connection with the Company’s revolving line of credit, as discussed in Note 8 in the Notes to Condensed Consolidated Financial Statements, the Company purchased a credit insurance policy that mitigates some of its credit risk, as the policy will pay either the Company or its lender on eligible claims filed on its outstanding receivables. On a regular basis, including at the time of sale, the Company performs credit evaluations of its customers. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company reserves against the accounts receivable on its condensed consolidated balance sheets and records a charge on its condensed consolidated statements of operations.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company had four customers and three customers that accounted for more than 10% of the Company’s outstanding trade receivables at both June 30, 2013, and December 31, 2012. These customers cumulatively represented approximately 64 % and 59% of the Company’s outstanding trade receivables, at June 30, 2013, and December 31, 2012, respectively. To date, the Company has not experienced collection difficulties from these customers.</font></p> </div>
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	85000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16123000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"> <font style="font-family:Times New Roman" size="2">The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, which are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</font></p> </div>
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.12
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2341000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64756000	shares
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16871000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1424000
	us-gaap	Goodwill Other Changes GoodwillOtherChanges	0
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-211000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-492000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Guarantee and Indemnification Arrangements</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company after December 31, 2002. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company’s technology infringes the intellectual property rights of a third party or claims that the sale or use of the Company’s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company generally provides for a one-year warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. During the year ended December 31, 2012, the Company provided for warranty obligations related to replacement costs for certain of its products that the Company identified were defective or had the potential of being defective. In connection with the warranty obligations provided for in relation to certain of its products during the year ended December 31, 2012, the Company filed a warranty claim against Fresenius, which Fresenius accepted. As a result, the Company recorded a current asset of $1.8 million on its consolidated balance sheets as of December 31, 2012 representing the full amount of the warranty claim against Fresenius as Fresenius will supply the Company with replacement products or credit notes for those defective or potentially defective products. The Company also wrote-down the value of certain unsalable inventory of $1.7 million related to these products as an offsetting warranty claim against Fresenius as of December 31, 2012. As of June 30, 2013, the Company no longer has a warranty claim against Fresenius and all unsalable inventory has been returned to Fresenius. During the three months ended March 31, 2013, the Company identified a separate production defect related to unsold inventory. The Company’s third party manufacturer has taken responsibility for the cost of replacing such damaged goods, therefore, the Company has borne no costs associated with these defects. Prior to these incidents, there have been very few warranty costs incurred. As a result, the Company did not accrue for any potential future warranty costs at June 30, 2013. In addition, the Company believes that the defective products and those that had the potential of being defective identified during the three months ended March 31, 2013 and during the year ended December 31, 2012 are isolated.</font></p> </div>
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	4387000
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	13000
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	19883000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16976000
	us-gaap	Interest Paid InterestPaid	203000
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	6149000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16976000
	us-gaap	Gross Profit GrossProfit	9046000
	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
	us-gaap	Revenue From Grants RevenueFromGrants	0
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12068000
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	180000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-56000
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	0
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4803000
	us-gaap	Net Income Loss NetIncomeLoss	-16976000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1341000
	us-gaap	Dilutive Securities DilutiveSecurities	0
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	10837000
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	13000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45739000
	us-gaap	Share Based Compensation ShareBasedCompensation	1554000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	31505000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0
	us-gaap	Other Noncash Expense OtherNoncashExpense	0
	us-gaap	Operating Expenses OperatingExpenses	21114000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14807000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	105000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	76000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	990000
	us-gaap	Interest Expense InterestExpense	238000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2151000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51171000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6206000
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	526000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	283000
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	101000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1554000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-193000
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	191000
	cers	Settlements Of Warranty Claims SettlementsOfWarrantyClaims	1272000
	cers	Safety Product Warranty Period SafetyProductWarrantyPeriod	P1Y
	cers	Warrant Liability Revaluation Gain Loss WarrantLiabilityRevaluationGainLoss	-4387000
	cers	Minimum Term Of Non Cancelable Operating Leases MinimumTermOfNonCancelableOperatingLeases	P1Y
	cers	Eligible To Receive Royalty Fee EligibleToReceiveRoyaltyFee	0.01	pure
	cers	Payment For Royalty PaymentForRoyalty	1600000
	cers	Expiration Of Non Cancelable Operating Leases Maximum Year ExpirationOfNonCancelableOperatingLeasesMaximumYear	2019
	cers	Inventory Life Finished Goods Period InventoryLifeFinishedGoodsPeriod	P2Y
	cers	Payment For Manufacturing Of Entity Products PaymentForManufacturingOfEntityProducts	7600000
	cers	Work In Process Inventory Life Period WorkInProcessInventoryLifePeriod	P1Y
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	11088000
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	9496000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10234000
	us-gaap	Share Based Compensation ShareBasedCompensation	1216000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53753000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9290000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14828000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53753000	shares
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	14000
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-2000
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	17915000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10741000
	us-gaap	Interest Paid InterestPaid	204000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10665000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2371000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-240000
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	60000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10741000
	us-gaap	Gross Profit GrossProfit	6827000
	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
	us-gaap	Revenue From Grants RevenueFromGrants	91000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9371000
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	63000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1294000
	us-gaap	Net Income Loss NetIncomeLoss	-10741000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2937000
	us-gaap	Dilutive Securities DilutiveSecurities	0
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1170000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	287000
	us-gaap	Other Noncash Expense OtherNoncashExpense	10000
	us-gaap	Operating Expenses OperatingExpenses	16289000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12652000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	76000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	25000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	17000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	763000
	us-gaap	Interest Expense InterestExpense	274000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1172000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9876000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3536000
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	175000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	402000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	101000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1216000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	226000
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	226000
	cers	Settlements Of Warranty Claims SettlementsOfWarrantyClaims	0
	cers	Performance Based Stock Options Awards PerformanceBasedStockOptionsAwards	0
	cers	Warrant Liability Revaluation Gain Loss WarrantLiabilityRevaluationGainLoss	-787000
	cers	Payment For Royalty PaymentForRoyalty	1300000
	cers	Payment For Manufacturing Of Entity Products PaymentForManufacturingOfEntityProducts	7500000
CY2010	cers	Proceeds From Landlord Financing Leasehold Improvement ProceedsFromLandlordFinancingLeaseholdImprovement	1100000
CY2012	us-gaap	Inventory Write Down InventoryWriteDown	1700000
CY2013Q1	cers	Payment For Manufacturing Of Entity Products PaymentForManufacturingOfEntityProducts	3600000
CY2012Q1	cers	Payment For Manufacturing Of Entity Products PaymentForManufacturingOfEntityProducts	3900000
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55236000	shares
CY2012Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	818000	shares
CY2012Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9165000	shares
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54418000	shares
CY2012Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9224000
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000
CY2012Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5581000
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1866000
CY2012Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-611000
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1907000
CY2012Q2	us-gaap	Gross Profit GrossProfit	3650000
CY2012Q2	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
CY2012Q2	us-gaap	Revenue From Grants RevenueFromGrants	0
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4799000
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2933000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-1907000
CY2012Q2	us-gaap	Dilutive Securities DilutiveSecurities	-3674000
CY2012Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2012Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5574000
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	8449000
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6686000
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41000
CY2012Q2	us-gaap	Interest Expense InterestExpense	135000
CY2012Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1712000
CY2012Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51000
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	674000
CY2012Q2	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2012Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2012Q2	cers	Warrant Liability Revaluation Gain Loss WarrantLiabilityRevaluationGainLoss	3674000
CY2012Q2	cers	Payment For Royalty PaymentForRoyalty	700000
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	54000
CY2013Q2	us-gaap	Interest Expense InterestExpense	107000
CY2013Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3506000
CY2013Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2013Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51000
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71928000	shares
CY2013Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2201000	shares
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10633000	shares
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	841000
CY2013Q2	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2013Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2013Q2	cers	Performance Based Stock Options Awards PerformanceBasedStockOptionsAwards	0
CY2013Q2	cers	Warrant Liability Revaluation Gain Loss WarrantLiabilityRevaluationGainLoss	686000
CY2013Q2	cers	Payment For Royalty PaymentForRoyalty	700000
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69727000	shares
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10150000
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16000
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7410000
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6670000
CY2013Q2	us-gaap	Goodwill Other Changes GoodwillOtherChanges	0
CY2013Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-157000
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6724000
CY2013Q2	us-gaap	Gross Profit GrossProfit	4403000
CY2013Q2	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
CY2013Q2	us-gaap	Revenue From Grants RevenueFromGrants	0
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7108000
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	438000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-6724000
CY2013Q2	us-gaap	Dilutive Securities DilutiveSecurities	-686000
CY2013Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5747000
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	11511000
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7954000

Files In Submission

Name	View Source	Status
0001193125-13-316994-index-headers.html	Edgar Link	pending
0001193125-13-316994-index.html	Edgar Link	pending
0001193125-13-316994.txt	Edgar Link	pending
0001193125-13-316994-xbrl.zip	Edgar Link	pending
cers-20130630.xml	Edgar Link	completed
cers-20130630.xsd	Edgar Link	pending
cers-20130630_cal.xml	Edgar Link	unprocessable
cers-20130630_def.xml	Edgar Link	unprocessable
cers-20130630_lab.xml	Edgar Link	unprocessable
cers-20130630_pre.xml	Edgar Link	unprocessable
d558058d10q.htm	Edgar Link	pending
d558058dex101.htm	Edgar Link	pending
d558058dex311.htm	Edgar Link	pending
d558058dex312.htm	Edgar Link	pending
d558058dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R43.xml	Edgar Link	unprocessable
R44.htm	Edgar Link	pending
R44.xml	Edgar Link	unprocessable
R45.htm	Edgar Link	pending
R45.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R46.xml	Edgar Link	unprocessable
R47.htm	Edgar Link	pending
R47.xml	Edgar Link	unprocessable
R48.htm	Edgar Link	pending
R48.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R49.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R50.htm	Edgar Link	pending
R50.xml	Edgar Link	unprocessable
R51.htm	Edgar Link	pending
R51.xml	Edgar Link	unprocessable
R52.htm	Edgar Link	pending
R52.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CERS
CERUS CORP Stock $cers

2013 Q2 Form 10-Q Financial Statement

#000119312513316994 Filed on August 02, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CERS CERUS CORP Stock $cers

2013 Q2 Form 10-Q Financial Statement

#000119312513316994 Filed on August 02, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CERS
CERUS CORP Stock $cers